Radiolabeled Compounds in the Development of Cytotoxic Agents

With the help of radiolabeled compounds, drug development can be made faster; especially with microdosing and radiopharmacokinetics, some elements of phase I and II trials necessary for conventional cancer drug development can be avoided. Imaging may proof the principle of actual targeting. However,...

Full description

Saved in:
Bibliographic Details
Published inCurrent pharmaceutical design Vol. 10; no. 24; pp. 2923 - 2934
Main Authors Kairemo, Kalevi, Tahtinen, Marja
Format Journal Article
LanguageEnglish
Published United Arab Emirates Bentham Science Publishers Ltd 01.09.2004
Subjects
Animals
Antineoplastic Agents - therapeutic use
Clinical Trials as Topic
Drug Design
Humans
Radioisotopes - therapeutic use
Tomography, Emission-Computed
Online AccessGet full text

Cover

More Information
Summary:With the help of radiolabeled compounds, drug development can be made faster; especially with microdosing and radiopharmacokinetics, some elements of phase I and II trials necessary for conventional cancer drug development can be avoided. Imaging may proof the principle of actual targeting. However, radiopharmacokinetics is dependent on the radionuclide, the radionuclide linker with the drug and the size of the drug molecule. Optimally, some of the drug molecule atoms may be replaced with a radionuclide that can be visualized. In this article drug development utilizing radionuclides both in PET and SPET has been reviewed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1381-6128
1873-4286
DOI:10.2174/1381612043383458